Drug
Kk2430
Kk2430: highest development phase Phase 1/2, developed by Kyowa Kirin. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Kyowa Kirin
Trials
| Drug | Phase | Indication |
|---|---|---|
| KK2430 NCT07629726 | Phase 1/2 | Hematologic Neoplasms |
Latest
No recent events.
Follow Kk2430 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.